- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approves Drug to Treat Hyperkalemia
The drug fills a void for patients with chronic kidney disease, including those with diabetes, who have high potassium levels.
Today, the FDA approved patiromer for oral suspension, to be marketed as Veltassa, to treat hyperkalemia, which results when potassium levels in the blood become too high.
The drug fills a void to treat roughly 3 million people who experience the build-up of potassium in the blood that places them at greater risk of heart arrhythmia.
Patiromer, a powder that mixes with water to create a tasteless, odorless liquid that patients drink once a day, brings potassium under control, giving kidney and heart disease patients the ability to be treated with RAAS inhibitors. The thought is that by using patiromer, patients will be able to take RAAS inhibitors and keep kidney disease from progressing, thus avoiding dialysis.
The drug is of interest to those with chronic kidney disease, including those with diabetes.
In approving patiromer, FDA’s Norman Stockbridge, MD, PhD, director of the Division of Cardiovascular and Renal Products in the Center for Drug and Evaluation Research, said, “Too much potassium in the blood can lead to dangerous, even fatal, changes in heart rhythm. It’s important to have treatment options for hyperkalemia available to patients.”
The drug works by binding potassium in the gastrointestinal tract; the potassium is then exited from the body through the normal excretion process. The most common adverse reactions in clinical trials were constipation, decreased magnesium levels in the blood, diarrhea, nausea, flatulence, and abdominal discomfort.
Patiromer carries a boxed warning because it binds with other orally administered drugs, which could decrease their absorption and reduce their effects. Other drugs should be taken 6 hours apart from patiromer.
The drug is manufactured by Relypsa.
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes
November 19th 2024Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers
November 13th 2024Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
